BackgroundWe previously set out the background and genesis of the proposed regulatory provisions of the "Proposal for a Directive of the European Parliament and of the Council on the Union Code…
It is increasingly difficult to discuss Intellectual Property (IP) without immediately bumping into questions of Artificial Intelligence (AI). The EU has been busy legislating in this field in recent…
An offer you can refuse?The recent judgment in Teva/Cephalon firmly anchors EU jurisprudence on pay-for-delay agreements. By upholding the sanctions imposed on the two companies for a series of side…
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions (PTE): Otsuka…
As we celebrate another year of the Unified Patent Court in action and head into the festive season, we invite our readers to put their UPC knowledge to the test in the Kluwer UPC Christmas Quiz 2025…
Brazil’s Ministry of Health and ABIFINA, the association representing local biosimilar and generic companies, have signed a patent-intelligence cooperation agreement aimed at improving the use of…
The UPC Paris Local Division has just released its much-anticipated decision in Merz v. Viatris, which at first glance looks like a familiar pharmaceutical case. A generic product moves through the…
EPO practice on added matter is well known to be strict, with many patents being revoked using this principle every year. Particularly tricky during EPO opposition proceedings is the “inescapable…
Two years after its launch, the Unified Patent Court has moved from promise to practice. What once looked like a procedural experiment has become a credible, fast, and intellectually rigorous forum—…
To ensure you don’t miss out on interesting IP law developments reported on our other blogs, we regularly provide an overview of the most-read posts from each of our IP law blogs. With…
